Comparison of Anemia Outcomes between SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Patients with Chronic Kidney Disease: Multi-institutional Cohort Study with Target Trial Emulation in Taiwan

被引：0
|
作者：
Shao, Shih-Chieh [1 ]
Hu, Jia-Chian [2 ]
Tsai, Daniel Hsiang-Te [3 ]
Chuang, Albert Tzu-Ming [2 ]
Liu, Kuan-Hung [4 ]
Lai, Edward Chia-Cheng [5 ]
机构：
[1] Keelung Chang Gung Mem Hosp, Keelung, Taiwan
[2] Natl Cheng Kung Univ, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Sch Pharm, Coll Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1193
引用
收藏
页码：537 / 537
页数：1
相关论文
共 50 条
  • [31] Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease
    Patorno, Elisabetta
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Kim, Dae H.
    Everett, Brendan M.
    Bessette, Lily G.
    Kim, Seoyoung C.
    DIABETES, 2019, 68
  • [32] REAL-WORLD SAFETY OF SGLT2 INHIBITORS, DPP-4 INHIBITORS, AND GLP-1 AGONISTS IN US VETERANS WITH AND WITHOUT CHRONIC KIDNEY DISEASE
    Narasaki, Yoko
    Kovesdy, Csaba
    You, Amy
    Potukuchi, Praveen
    Dashputre, Ankur
    Sumida, Keichii
    Thomas, Fridtjof
    Streja, Elani
    Kalantar-Zadeh, Kam
    Rhee, Connie
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S121 - S122
  • [33] SGLT2 inhibitors associated with decreased risk of nephrolithiasis compared to GLP-1 receptor agonists: An active comparator, new user cohort study
    Martinez-De la Torre, Adrian
    Burden, Andrea M.
    Pottegard, Anton
    Lund, Lars Christian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 14 - 14
  • [34] EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE
    Krishnan, Arunkumar
    Mukherjee, Diptasree
    Althwanay, Aldanah
    Woreta, Tinsay A.
    Alqahtani, Saleh A.
    GASTROENTEROLOGY, 2024, 166 (05) : S474 - S475
  • [35] Relation between Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists and Renal Functions among Japanese Diabetics
    Toyoda, Masao
    Kobayashi, Kazuo
    DIABETES, 2023, 72
  • [36] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [37] SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-analysis
    Cao, Hongwei
    Liu, Tao
    Wang, Li
    Ji, Qiuhe
    DIABETES, 2022, 71
  • [38] Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
    Scheen, Andre J.
    DIABETES EPIDEMIOLOGY AND MANAGEMENT, 2024, 13
  • [39] Treatment discontinuation among users of SGLT2 inhibitors and GLP-1 receptor agonists in a national population of patients with type 2 diabetes
    Lim, C. -E.
    Pasternak, B.
    Eliasson, B.
    Ueda, P.
    DIABETOLOGIA, 2024, 67 : S205 - S205
  • [40] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
    Azoulay, Laurent
    Simms-Williams, Nikita
    Yin, Hui
    Lu, Sally
    Treves, Nir
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
12345